Evolving management of positive regional lymph nodes in melanoma: Past, present and future directions

  • Rachel A. Fayne | raf145@med.miami.edu Division of Surgical Oncology, Dewitt-Daughtry Department of Surgery, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, United States.
  • Francisco I. Macedo Department of Surgery, North Florida Regional Medical Center, University of Central Florida College of Medicine, Miami, FL, United States.
  • Steven E. Rodgers Division of Surgical Oncology, Dewitt-Daughtry Department of Surgery, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, United States.
  • Mecker G. Möller Division of Surgical Oncology, Dewitt-Daughtry Department of Surgery, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, United States.

Abstract

Sentinel lymph node (SLN) biopsy has become the standard of care for lymph node staging in melanoma and the most important predictor of survival in clinically node-negative disease. Previous guidelines recommend completion lymph node dissection (CLND) in cases of positive SLN; however, the lymph nodes recovered during CLND are only positive in a minority of these cases. Recent evidence suggests that conservative management (i.e. observation) has similar outcomes compared to CLND. We sought to review the most current literature regarding the management of SLN in metastatic melanoma and to discuss potential future directions.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.
Published
2019-11-28
Info
Issue
Section
Reviews
Keywords:
Melanoma, sentinel lymph node biopsy, completion lymph node dissection.
Statistics
  • Abstract views: 560

  • PDF: 595
  • HTML: 16
How to Cite
Fayne, R. A., Macedo, F. I., Rodgers, S. E., & Möller, M. G. (2019). Evolving management of positive regional lymph nodes in melanoma: Past, present and future directions. Oncology Reviews, 13(2). https://doi.org/10.4081/oncol.2019.433